Kodiak Sciences Inc. (KOD) vs Rhythm Pharmaceuticals, Inc. (RYTM)
A side-by-side comparison of Kodiak Sciences Inc. and Rhythm Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KOD
Kodiak Sciences Inc.
$92.62HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
RYTM
Rhythm Pharmaceuticals, Inc.
$90.20HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Total return — KOD vs RYTM
growth of $100 · dividends reinvested · last 8yKOD +4521.2% (+61.5%/yr)RYTM +222.5% (+15.8%/yr)KOD compounded faster over this window
Log scale — wide-divergence pair
KOD RYTM
KOD vs RYTM: by the numbers
- •RYTM is the larger company ($6.19B vs $5.80B market cap).
- •Both run net losses; KOD's is the smaller (0.00% vs -85.59% net margin).
Metrics side by side
Valuation
| Metric | KOD | RYTM |
|---|---|---|
| P/S ratio | N/A | 25.79 |
| P/B ratio | 94.87 | 60.08 |
Profitability
| Metric | KOD | RYTM |
|---|---|---|
| Gross margin | 0.00% | 89.00% |
| Operating margin | 0.00% | -101.19% |
| Net margin | 0.00% | -85.59% |
| ROE | -396.09% | -94.50% |
| ROIC | -115.23% | -63.96% |
Growth (annualized)
| Metric | KOD | RYTM |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 278.53% |
| Total return CAGR (5Y) | 36.19% | 49.95% |
Frequently asked
- How have KOD and RYTM total returns compared?
- Over the past 5 years, KOD delivered 36.19% and RYTM delivered 49.95% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Kodiak Sciences ROERhythm Pharmaceuticals ROEKodiak Sciences operating marginRhythm Pharmaceuticals operating marginKodiak Sciences revenue growthRhythm Pharmaceuticals revenue growthKodiak Sciences free cash flowRhythm Pharmaceuticals free cash flow
Kodiak Sciences & Rhythm Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.